These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 32447345)

  • 1. Cytokine IL-36γ improves CAR T-cell functionality and induces endogenous antitumor response.
    Li X; Daniyan AF; Lopez AV; Purdon TJ; Brentjens RJ
    Leukemia; 2021 Feb; 35(2):506-521. PubMed ID: 32447345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NKT Cells Coexpressing a GD2-Specific Chimeric Antigen Receptor and IL15 Show Enhanced
    Xu X; Huang W; Heczey A; Liu D; Guo L; Wood M; Jin J; Courtney AN; Liu B; Di Pierro EJ; Hicks J; Barragan GA; Ngai H; Chen Y; Savoldo B; Dotti G; Metelitsa LS
    Clin Cancer Res; 2019 Dec; 25(23):7126-7138. PubMed ID: 31484667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma.
    Makkouk A; Yang XC; Barca T; Lucas A; Turkoz M; Wong JTS; Nishimoto KP; Brodey MM; Tabrizizad M; Gundurao SRY; Bai L; Bhat A; An Z; Abbot S; Satpayev D; Aftab BT; Herrman M
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34916256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Constitutively active MyD88/CD40 costimulation enhances expansion and efficacy of chimeric antigen receptor T cells targeting hematological malignancies.
    Collinson-Pautz MR; Chang WC; Lu A; Khalil M; Crisostomo JW; Lin PY; Mahendravada A; Shinners NP; Brandt ME; Zhang M; Duong M; Bayle JH; Slawin KM; Spencer DM; Foster AE
    Leukemia; 2019 Sep; 33(9):2195-2207. PubMed ID: 30816327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chimeric cytokine receptor enhancing PSMA-CAR-T cell-mediated prostate cancer regression.
    Weimin S; Abula A; Qianghong D; Wenguang W
    Cancer Biol Ther; 2020 Jun; 21(6):570-580. PubMed ID: 32208880
    [No Abstract]   [Full Text] [Related]  

  • 6. Engineering genetic devices for in vivo control of therapeutic T cell activity triggered by the dietary molecule resveratrol.
    Yang L; Yin J; Wu J; Qiao L; Zhao EM; Cai F; Ye H
    Proc Natl Acad Sci U S A; 2021 Aug; 118(34):. PubMed ID: 34404729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD40 Ligand-Modified Chimeric Antigen Receptor T Cells Enhance Antitumor Function by Eliciting an Endogenous Antitumor Response.
    Kuhn NF; Purdon TJ; van Leeuwen DG; Lopez AV; Curran KJ; Daniyan AF; Brentjens RJ
    Cancer Cell; 2019 Mar; 35(3):473-488.e6. PubMed ID: 30889381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities.
    Christodoulou I; Ho WJ; Marple A; Ravich JW; Tam A; Rahnama R; Fearnow A; Rietberg C; Yanik S; Solomou EE; Varadhan R; Koldobskiy MA; Bonifant CL
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34896980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CAR exosomes derived from effector CAR-T cells have potent antitumour effects and low toxicity.
    Fu W; Lei C; Liu S; Cui Y; Wang C; Qian K; Li T; Shen Y; Fan X; Lin F; Ding M; Pan M; Ye X; Yang Y; Hu S
    Nat Commun; 2019 Sep; 10(1):4355. PubMed ID: 31554797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. rhIL-7-hyFc, a long-acting interleukin-7, improves efficacy of CAR-T cell therapy in solid tumors.
    Li D; Liang T; Hutchins LE; Wolfarth AA; Ferrando-Martinez S; Lee BH; Ho M
    J Immunother Cancer; 2024 Jul; 12(7):. PubMed ID: 39043602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MyD88/CD40 signaling retains CAR T cells in a less differentiated state.
    Prinzing B; Schreiner P; Bell M; Fan Y; Krenciute G; Gottschalk S
    JCI Insight; 2020 Nov; 5(21):. PubMed ID: 33148882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pre-depletion of TRBC1+ T cells promotes the therapeutic efficacy of anti-TRBC1 CAR-T for T-cell malignancies.
    Zhang C; Palashati H; Rong Z; Lin N; Shen L; Liu Y; Li S; Yu B; Yang W; Lu Z
    Mol Cancer; 2020 Nov; 19(1):162. PubMed ID: 33218364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD27 enhances the killing effect of CAR T cells targeting trophoblast cell surface antigen 2 in the treatment of solid tumors.
    Chen H; Wei F; Yin M; Zhao Q; Liu Z; Yu B; Huang Z
    Cancer Immunol Immunother; 2021 Jul; 70(7):2059-2071. PubMed ID: 33439295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multispecific Targeting with Synthetic Ankyrin Repeat Motif Chimeric Antigen Receptors.
    Balakrishnan A; Rajan A; Salter AI; Kosasih PL; Wu Q; Voutsinas J; Jensen MC; Plückthun A; Riddell SR
    Clin Cancer Res; 2019 Dec; 25(24):7506-7516. PubMed ID: 31548346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ERBB2-CAR-Engineered Cytokine-Induced Killer Cells Exhibit Both CAR-Mediated and Innate Immunity Against High-Risk Rhabdomyosarcoma.
    Merker M; Wagner J; Kreyenberg H; Heim C; Moser LM; Wels WS; Bonig H; Ivics Z; Ullrich E; Klingebiel T; Bader P; Rettinger E
    Front Immunol; 2020; 11():581468. PubMed ID: 33193388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Construction of a new anti-CD19 chimeric antigen receptor and the anti-leukemia function study of the transduced T cells.
    An N; Tao Z; Li S; Xing H; Tang K; Tian Z; Rao Q; Wang M; Wang J
    Oncotarget; 2016 Mar; 7(9):10638-49. PubMed ID: 26840021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity.
    Adusumilli PS; Cherkassky L; Villena-Vargas J; Colovos C; Servais E; Plotkin J; Jones DR; Sadelain M
    Sci Transl Med; 2014 Nov; 6(261):261ra151. PubMed ID: 25378643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies.
    Rodgers DT; Mazagova M; Hampton EN; Cao Y; Ramadoss NS; Hardy IR; Schulman A; Du J; Wang F; Singer O; Ma J; Nunez V; Shen J; Woods AK; Wright TM; Schultz PG; Kim CH; Young TS
    Proc Natl Acad Sci U S A; 2016 Jan; 113(4):E459-68. PubMed ID: 26759369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eradication of Neuroblastoma by T Cells Redirected with an Optimized GD2-Specific Chimeric Antigen Receptor and Interleukin-15.
    Chen Y; Sun C; Landoni E; Metelitsa L; Dotti G; Savoldo B
    Clin Cancer Res; 2019 May; 25(9):2915-2924. PubMed ID: 30617136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gamma-Delta CAR-T Cells Show CAR-Directed and Independent Activity Against Leukemia.
    Rozenbaum M; Meir A; Aharony Y; Itzhaki O; Schachter J; Bank I; Jacoby E; Besser MJ
    Front Immunol; 2020; 11():1347. PubMed ID: 32714329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.